Finally, although the contribution of TLR4/NFkB signaling to NASH and hepatic fibrosis is well known, in future studies, we will validate the protective role of ALT-100 mAb via eNAMPT/TLR4 utilizing TLR4 knockdown or inhibitors. The gene discussed is TLR4; the disease is metabolic dysfunction-associated steatohepatitis.